BRIEF-Immunic's Oral Imu-856 Demonstrated Dose-Dependent Increase Of Glp-1

Reuters
02-20
BRIEF-Immunic's Oral Imu-856 Demonstrated Dose-Dependent Increase Of Glp-1

Feb 20 (Reuters) - Immunic Inc IMUX.O:

  • IMMUNIC'S ORAL IMU-856 DEMONSTRATED DOSE-DEPENDENT INCREASE OF GLP-1 IN CELIAC DISEASE PATIENTS AND CORRESPONDING EFFECTS IN PRECLINICAL TESTING

  • IMMUNIC INC: DOSE-DEPENDENT REDUCTION OF BODY WEIGHT GAIN AND FOOD CONSUMPTION OBSERVED IN PRECLINICAL STUDY

  • IMMUNIC: DOSE-DEPENDENT INCREASE OF ENDOGENOUS GLP-1 LEVELS OBSERVED IN POST HOC ANALYSIS OF PATIENTS FROM PHASE 1B CLINICAL TRIAL IN CELIAC DISEASE

Source text: ID:nPn12yQH3a

Further company coverage: IMUX.O

((Reuters.Briefs@thomsonreuters.com;))

免责声明:投资有风险,本文并非投资建议,以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请,作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考,不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证,投资者应自行研究并在投资前寻求专业建议。

热议股票

  1. 1
     
     
     
     
  2. 2
     
     
     
     
  3. 3
     
     
     
     
  4. 4
     
     
     
     
  5. 5
     
     
     
     
  6. 6
     
     
     
     
  7. 7
     
     
     
     
  8. 8
     
     
     
     
  9. 9
     
     
     
     
  10. 10